Evaluation of Vancomycin in Combination with Piperacillin-Tazobactam or Oxacillin against Clinical Methicillin-Resistant Staphylococcus aureus Isolates and Vancomycin-Intermediate S. aureus Isolates
            <i>In Vitro</i>

Dilworth, Thomas J; Sliwinski, Jora; Ryan, Keenan; Dodd, Melanie; Mercier, Renée-Claude

doi:10.1128/aac.01888-13

Cited by 41 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The beta-lactam concentrations used in the combinations were 0.5 ϫ the MICs listed below or the biological free peak concentrations presented in the text, whichever one was lower. (A) Strain 8019; ORI MIC, 0.125 g/ml; AMP MIC, Ͼ128 g/ml; ERT MIC, Ͼ32 g/ml; CPT MIC, 32 g/ml; (B) strain R6815; ORI MIC, 0.125 g/ml; AMP MIC, Ͼ64 g/ml; ERT MIC, Ͼ32 g/ml; CPT MIC, Ͼ64 g/ml; (C) strain R7164; ORI MIC, 0.125 g/ml; AMP MIC, 8 g/ml; ERT MIC, Ͼ32 g/ml; CPT MIC, been demonstrated when beta-lactams were combined with VAN or DAP, and the findings of our study suggest that beta-lactams confer similar benefits upon ORI in vitro (22,23,(25)(26)(27)(32)(33)(34)(35).…”

Section: Discussionsupporting

confidence: 64%

“…In vitro time-kill experiments have demonstrated the concentration-dependent bactericidal activity of ORI against daptomycin-nonsusceptible (DNS) MRSA, VAN-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), and VRE in 24-h time-kill experiments (17)(18)(19)(20). Recent data suggest that lipopeptides and glycopeptides demonstrate enhanced activity against these resistant, Gram-positive organisms when beta-lactams are added (9,13,15,16,(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). However, the activity of ORI in combination with beta-lactams against multidrug-resistant MRSA or VRE strains has yet to be evaluated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

Smith

Yim

Raut

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Oritavancin possesses activity against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). In vitro data suggest synergy between beta-lactams (BLs) and vancomycin or daptomycin, agents similar to oritavancin. We evaluated the activities of BLs combined with oritavancin against MRSA and VRE. Oritavancin MICs were determined for 30 strains, 5 each of MRSA, daptomycin-nonsusceptible (DNS) MRSA, vancomycin-intermediate MRSA (VISA), heteroresistant VISA (hVISA), vancomycin-resistant Enterococcus faecalis, and vancomycin-resistant Enterococcus faecium. Oritavancin MICs were determined in the presence of subinhibitory concentrations of BLs. Oritavancin combined with ceftaroline, cefazolin, or nafcillin was evaluated for lethal synergy against MRSA, and oritavancin combined with ceftaroline, ampicillin, or ertapenem was evaluated for lethal synergy against VRE in 24-h time-kill assays. Oritavancin at 0.5؋ the MIC was combined with BLs at 0.5؋ the MIC or the biological free peak concentration, whichever one was lower. Synergy was defined as a >2-log 10 -CFU/ml difference between the killing achieved with the combination and that achieved with the most active single agent at 24 h. Oritavancin MICs were <0.125 g/ml for all MRSA isolates except three VISA isolates with MICs of 0.25 g/ml. Oritavancin MICs for VRE ranged from 0.03 to 0.125 g/ml. Oritavancin in combination with ceftaroline was synergistic against all MRSA phenotypes and statistically superior to all other combinations against DNS MRSA, hVISA, and MRSA isolates (P < 0.02). Oritavancin in combination with cefazolin and oritavancin in combination with nafcillin were also synergistic against all MRSA strains. Synergy between oritavancin and all BLs was revealed against VRE strain 8019, while synergy between oritavancin and ampicillin or ertapenem but not ceftaroline was demonstrated against VRE strain R7164. The data support the potential use of oritavancin in combination with BLs, especially oritavancin in combination with ceftaroline, for the treatment of infections caused by MRSA. The data from the present study are not as strong for oritavancin in combination with BLs for VRE. Further study of both MRSA and VRE in more complex models is warranted. O ritavancin (ORI) is a novel lipoglycopeptide antibiotic recently approved by the Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) (1-3). Unique to ORI among the agents approved for use for the treatment of ABSSSIs, the antibiotic is administered as a single dose of 1,200 mg as the entire treatment course. ORI is active against a wide range of Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) (4). It possesses three mechanisms of action, acting via inhibition of both transglycosylation and transpeptidation at the cell wall, along with disruption of the cell membrane (5). ORI is a potent agent against Gram-positive organisms. Against ov...

show abstract

Section: Discussionsupporting

confidence: 64%

mentioning

confidence: 99%

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

Smith

Yim

Raut

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Another in vitro pharmacokinetic/ pharmacodynamic model by Leonard demonstrated increased bactericidal activity against MRSA and hVISA using a combination of VAN and nafcillin compared to VAN alone (12). Piperacillin-tazobactam in combination with VAN has also demonstrated synergistic activity against MRSA and VISA isolates in time-kill studies (13,14).BLs are often empirically added to VAN as Gram-negative coverage for many disease states, including pneumonia and septic shock (15, 16). However, despite extensive clinical use of these regimens, little is known about the impact of BLs on VAN activity against MRSA.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

β-Lactams Enhance Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus Bacteremia Compared to Vancomycin Alone

Dilworth

Ibrahim

Hall

et al. 2014

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with increased health care costs, morbidity, and mortality as well as worse treatment outcomes than methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (1, 2). Moreover, a recent study found that 88% of invasive, nosocomial MRSA infections involved a positive blood culture (3). Vancomycin (VAN) has been the mainstay of MRSA treatment for over 40 years, but concerns regarding the efficacy of VAN against MRSA are mounting (4). VAN has been shown to have slow bactericidal activity, poor antistaphylococcal activity, poor tissue penetration, and high rates of infection relapse (1,(5)(6)(7)(8)(9)(10).Given the widespread use of VAN for treating MRSA infections despite its questionable efficacy, several in vitro studies have explored combination therapy using VAN with a ␤-lactam (BL) against MRSA. An in vitro pharmacokinetic/pharmacodynamic (PK/PD) model simulating in vivo antibiotic exposure demonstrated that VAN in combination with cefazolin improved antibacterial activity against MRSA and heterogeneous vancomycin intermediate-susceptible Staphylococcus aureus (hVISA) isolates compared to VAN alone (11). Another in vitro pharmacokinetic/ pharmacodynamic model by Leonard demonstrated increased bactericidal activity against MRSA and hVISA using a combination of VAN and nafcillin compared to VAN alone (12). Piperacillin-tazobactam in combination with VAN has also demonstrated synergistic activity against MRSA and VISA isolates in time-kill studies (13,14).BLs are often empirically added to VAN as Gram-negative coverage for many disease states, including pneumonia and septic shock (15, 16). However, despite extensive clinical use of these regimens, little is known about the impact of BLs on VAN activity against MRSA. While in vitro studies have demonstrated synergy between BLs and VAN against MRSA isolates, studies looking at clinical outcomes of these combinations have not been performed. The objective of this study was to examine the impact of combination therapy with VAN and a ␤-lactam for Ն24 h on the microbiological eradication of MRSA bacteremia compared to VAN alone. MATERIALS AND METHODSStudy design, setting, and population. A retrospective cohort study was conducted at the University of New Mexico Hospital (UNMH), a 646-bed tertiary care academic medical center in Albuquerque, NM. This study was approved by the University of New Mexico Human Research Review Committee. This study conforms to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) recommendations for reporting cohort studies (17). Patients were eligible for study inclusion if they met the following criteria: (i) they were admitted to UNMH between January 2005 and December 2012; (ii) they were Ն18 years of age at the time of admission; (iii) they had had at least one blood culture positive for MRSA with a VAN MIC of Յ2 mg/liter by the BD Phoenix or Vitek automated microbiological system, and the isolate was available for further microbi...

show abstract

“…Yapılan çalışmalarda Öksüz ve arkadaşları 14 Kullanıma giren yeni antibiyotiklere rağmen MRSA enfeksiyonla¬rında temel tedavi seçeneği glikopeptidlerdir. Glikopeptid direnci ilk kez 2002 yılında ortaya çıkmış olup, son yıllarda dünyanın değişik bölgelerinde giderek artan oranlarda VISA/hVISA izolatları rapor edilmektedir 16,17 . VISA izolatlarının rutin antimikrobiyal duyarlılık testleri ile belirlenememesi ve vankomisinin oldukça yaygın olarak kullanılıyor olması, ülkemizde belirli aralıklarla azalmış vankomisin duyarlılığı araştırılmasını gerekli kılmaktadır.…”

Section: Discussionunclassified

Metisiline Dirençli Staphylococcus aureus İzolatlarının Antibiyotik Direnci ve Azalmış Vankomisin Duyarlılığının Araştırılması: Çok Merkezli Bir Çalışma

Çıkman¹,

Aydın

Gülhan³

et al. 2015

Mikrobiyol Bul

View full text Add to dashboard Cite

Evaluation of Vancomycin in Combination with Piperacillin-Tazobactam or Oxacillin against Clinical Methicillin-Resistant Staphylococcus aureus Isolates and Vancomycin-Intermediate S. aureus Isolates In Vitro

Abstract: Vancomycin with piperacillin-tazobactam is used as empirical therapy for critically ill patients. Studies of this combination against methicillin-resistant

Cited by 41 publications

References 24 publications

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

β-Lactams Enhance Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus Bacteremia Compared to Vancomycin Alone

Metisiline Dirençli Staphylococcus aureus İzolatlarının Antibiyotik Direnci ve Azalmış Vankomisin Duyarlılığının Araştırılması: Çok Merkezli Bir Çalışma

Contact Info

Product

Resources

About